Earnings Labs

Flexible Solutions International, Inc. (FSI)

Q2 2022 Earnings Call· Tue, Aug 16, 2022

$6.53

+0.31%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

-2.15%

1 Week

-7.09%

1 Month

-36.57%

vs S&P

-20.35%

Transcript

Operator

Operator

Good day, everyone and welcome to today’s Flexible Solutions International Second Quarter 2022 Financial Results Conference Call. Please note, this call is being recorded. And now it is my pleasure to turn the conference over to Mr. Dan O’Brien. Please go ahead, sir. Daniel O’Brien: Thank you, Jess. Good morning. This is Dan O’Brien, CEO of Flexible Solutions. Safe Harbor provision; the Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Certain of the statements contained herein which are not historical facts are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted either positively or negatively by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission. Welcome to the Q2 conference call. I'd like to update our company condition and our product lines, along with what, in our opinion, might occur in the third and fourth quarters of 2022. Then I'll comment on our financials. For the COVID virus, we are not experiencing problems due to the virus other than mild cases in our employee ranks and shipping delays when Asian ports experienced lockdowns. Our NanoChem division, NCS, represents more than half the revenue of FSI. This division makes thermal polyaspartic acid called TPA for short, a biodegradable polymer with many valuable uses. NCS also manufactures SUN 27 and N Savr 30 which are used to reduce nitrogen fertilizer loss from soil. In 2022, NCS started toll operations using the spray dryer we installed over the last several years. TPA, it's used in agriculture to significantly increase crop yield. It acts by slowing crystal growth between fertilizer ions and other ions in the soil, resulting…

Operator

Operator

Our first question comes from William Gregozeski at Greenridge Global.

William Gregozeski

Analyst

Dan, great quarter. In regards to the Florida, LLC, what percent -- I know you don’t like giving too many specifics on this but I was under the impression most of their product was purchased from FSI. And you mentioned that they were having trouble with their higher cost of goods. So I’m trying to reconcile what that issue might be for them, if they’re just having a hard time passing their price increases on that they’re getting from you guys or if it’s something else? Daniel O’Brien: Actually, you hit the nail on the head. We manufacture for them under contract. And our contract allows us to raise prices as our input costs go up. They are having trouble passing that along to their customers. And I mean, they have raised prices as far as they can but there are -- there is stress in their selling and we are working with them to the best of our abilities inside the contract but I'd be giving money to .

William Gregozeski

Analyst

Okay. So at least for the near future, I mean, the low 20 gross margin range is probably going to be continued for them on their results? Daniel O’Brien: Yes. I would say that's probably correct. That's absent another bout of amazing inflation. If inflation in raw material cost stops or backs off, they'll be able to increase their margins again. But at the moment, earned margin is probably what you'll see.

William Gregozeski

Analyst

Okay. And there's been all kinds of news about the droughts in the Western U.S. Is there any interest in using WaterSavr to help with that problem? And obviously, it would be a fix for it. But is anybody pursuing that? Daniel O’Brien: We have a part-time salesman handling all of the inquiries. But Bill, this is the crazy situation here. We've been pitching WaterSavr to Western America for 20 years and prove that it works. 20 years ago, there was 100 feet more water in those dams. And that's when they should have started using it because this WaterSavr does not generate water, it only saves it. And there's not a lot of water left to save. So, I guess I’ve got a case of schadenfreude but it’s really not the answer to their problems now. The answer to their problem is to get their reservoirs full again.

Operator

Operator

We'll move next to Tim Clarkson with Van Clemens Capital.

Tim Clarkson

Analyst

Dan, just wanted to know when do you think this -- is it Lygos investment, when do you think that will be completed? Daniel O’Brien: Yes. On the merger agreement, this is an agreement that has its contracts. The contract states that the merger must be complete by September 30. If it is not complete by September 30, it has to be either extended or it goes away. So I guess what I'm saying is that expect it to be completed by September 30 or not to be completed.

Tim Clarkson

Analyst

Okay. And in terms of now the -- what was the kind of the logic of doing this deal again? Is it -- go ahead. Daniel O’Brien: Yes. No, it's a good question because although it hasn't been well received by the market, the logic is pretty solid. The opportunities in a combined company that can start with corn sugar grown in the United States, ferment that into aspartic acid at a price lower than the current oil price of aspartic acid and then utilize it to make quite a variety of polyaspartate and other chemistries at the Flexible Solutions factories results in a value-added specialty chemical platform that is specifically attractive to the detergent companies to start with, who are trying to become 100% sustainable. And these groups of the detergent companies -- really can't name names but they're all the big ones, they are trying to go completely sustainable. And the need is for hundreds of thousands of metric tons of finished products from a company just like the Flexible Solutions-Lygos combination. Now obviously, it's a big project to -- getting to hundreds of thousands of tons from 5s of thousands of tons but that's the logic behind this is to not make a generic chemical like aspartic acid but to make a specialty chemical from aspartic acid and to control the entire roof from sugar all the way to the specialty chemicals. So that was -- that's the theory behind it and it's a good business plan.

Tim Clarkson

Analyst

Right. Now what -- I mean, is this reasonable that this would all turn profitable in 2 years or 5 years? Or maybe you don’t even know. Daniel O’Brien: Well, this is a point where I have to say to you, please read the S-4 because there are forward-looking statements in the S-4. It's -- sadly, it's a 500-page document which I have not memorized yet. But yes, there are forward-looking statements. There's a point where profitability is expected. I'm pretty sure it's inside 5 years but please, I can't be quoted on that.

Tim Clarkson

Analyst

Sure. And just looking at -- again, I’m a big picture guy. What’s the biggest risk? I mean, it doesn’t sound like the risk is whether there’s demand for the product. It sounds like the risk is whether you can create -- do it on a bigger scale, right? Daniel O’Brien: Yes, it's an execution risk.

Tim Clarkson

Analyst

Okay. Okay. And obviously, you must believe that based on some of the execution successes on a smaller scale that already demonstrate at least a reasonable probability that they’re going to be able to do it, right? Daniel O’Brien: Yes.

Tim Clarkson

Analyst

Otherwise, it’d be kind of a foolish venture. So -- right? I mean, that’s kind of the obvious but obviously has to be stated out loud.. Daniel O’Brien: Yes, you're right. It's -- we believe it's a reasonable opportunity and...

Tim Clarkson

Analyst

And Flexible Solutions, the fact that Flexible Solutions just coming into this is because you already give these guys a good-sized market and can help facilitate them getting up to the scale. Is that the piece that Flexible Solutions brings to it? Daniel O’Brien: Yes, that's the piece we bring is a route to market at a much higher price. If they just make -- if Lygos went ahead on their own and made aspartic acid, they would get 1 price per ton because it would be more or less a commodity organic asset. By owning Flexible Solutions and having the route to the specialty chemical sector that Flexible Solutions services, the selling price per ton more than doubles and the margin increases dramatically as well.

Tim Clarkson

Analyst

Right. And you’ve done some -- raised enough, what these bond raises and stuff that at least for the reasonable foreseeable future, you’ve got enough money to try to make this happen. Daniel O’Brien: That would be accurate. That's -- it might not be as much as some of the synthetic chemistry companies have raised or synthetic biochem. But the fact that the Flexible Solutions plant already exists ready to do the second half of the processing is a pretty significant benefit compared to what other companies in the sector face.

Tim Clarkson

Analyst

Right. Right now just leaving off the detergent application, I mean, is there a sizable market just for the proven fertilizer application if the product was more available? Daniel O’Brien: Yes. There's also markets that we've never addressed but one of them is actually the international market for aspartame. Aspartame, you may have personal feelings about it. But if it were made from sustainable chemicals, it would at least be somewhat safer than making it from oil-based chemicals.

Tim Clarkson

Analyst

Yes. I’m sure that would appeal to a lot of people of all kinds of beliefs about nutritional items that may or may not be based on science but sounds -- which is a big part of that game. So anyhow, well, I appreciate it. I mean, I’m very hopeful that this is going to -- off and I’m watching it and got still some money in it and really admire what you're doing. So keep at it.

Operator

Operator

Our next question comes from .

Unidentified Analyst

Analyst

Congratulations on a beautiful quarter. My question is pretty simple. I spent a number of hours, like you said, going through that S-4 which was very, very lengthy. One question I couldn't get answered is, how close are they to commercialization? Daniel O’Brien: Yes. And it's probably not a question I should answer.

Unidentified Analyst

Analyst

Well, it’s a pretty important question quite honestly. Daniel O’Brien: Yes. I can have an opinion that they are...

Unidentified Analyst

Analyst

That’s close enough for me. I would like your opinion, yes. Daniel O’Brien: I think my opinion is -- yes -- my opinion is that it's the full commercialization is within 5 years and how much earlier than that, I'm not certain.

Unidentified Analyst

Analyst

Okay. Yes, because I mean, we’re taking a beautiful company like FSI which is growing, profitable and we turn them into an R&D company where with even $160 million, like you just stated your sector peers, biochem tried to do a synthetic stuff. One company I follow, they spent over $1 billion and still not profitable. So $160 million sounds like a lot of money but when you start getting into this, it might not be enough money. Daniel O’Brien: Might not but here's a theory that I have in this world. Going back to the very beginning of Flexible Solutions, my father and I funded the original private company with $500. And the point was there is no more money coming, make it work. Sometimes bootstrapping and being forced to work inside a tight budget is better for a company than having unlimited funds. I don't know.

Unidentified Analyst

Analyst

I see the -- I’d certainly see the benefit in that. Absolutely. And the potential -- discounting the benefit -- the potential -- the potential is ginormous. I don’t think anybody questions that. The question is, are we going to become a disaster because it’s going to take 7 years or 8 years and we’ve got to raise another couple of hundred million. And all along, we’re going to become a money-losing R&D company. Daniel O’Brien: Well, Dennis, unfortunately, that's stuff I really can't comment on because it would be forward stuff that I actually don't know the answers to. And I really don't want to put us in legal jeopardy along with financials.

Unidentified Analyst

Analyst

No, no. I wouldn’t want you to do that as well. Listen, again, a beautiful quarter. We have still a lot of reservations going forward. But again, I appreciate you taking the time. Daniel O’Brien: You're welcome, Dennis and not over till the shareholder meeting. So we'll keep working and we'll keep showing you why it's a good idea.

Operator

Operator

Mr. O’Brien, at this time, I do not have any other questions holding. I will turn the conference back to you for any additional or closing comments. Daniel O’Brien: Thank you, Jess. Everybody, thanks very much for listening in today and for your questions. Hopefully, we’ll be talking again at the end of third quarter and thank you very much.

Operator

Operator

Ladies and gentlemen, that will conclude today's program. We thank you for your participation. You may disconnect at this time.